Jane Street’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.05M | Sell |
72,600
-85,600
| -54% | -$1.23M | ﹤0.01% | 6385 |
|
|
2025
Q4 | $2.25M | Buy |
158,200
+15,500
| +11% | +$152K | ﹤0.01% | 4581 |
|
|
2025
Q3 | $1.12M | Buy |
142,700
+120,100
| +531% | +$855K | ﹤0.01% | 6070 |
|
|
2025
Q2 | $129K | Sell |
22,600
-2,200
| -9% | -$14.2K | ﹤0.01% | 8841 |
|
|
2025
Q1 | $202K | Buy |
+24,800
| New | +$229K | ﹤0.01% | 8433 |
|
|
2024
Q4 | – | Sell |
-50,600
| Closed | -$540K | – | 9787 |
|
|
2024
Q3 | $540K | Buy |
+50,600
| New | +$551K | ﹤0.01% | 7051 |
|
|
2023
Q4 | – | Sell |
-33,200
| Closed | -$404K | – | 9355 |
|
|
2023
Q3 | $404K | Buy |
33,200
+12,400
| +60% | +$160K | ﹤0.01% | 6604 |
|
|
2023
Q2 | $261K | Buy |
20,800
+8,400
| +68% | +$99.7K | ﹤0.01% | 7329 |
|
|
2023
Q1 | $138K | Sell |
12,400
-61,300
| -83% | -$756K | ﹤0.01% | 8062 |
|
|
2022
Q4 | $900K | Sell |
73,700
-77,500
| -51% | -$872K | ﹤0.01% | 5145 |
|
|
2022
Q3 | $1.58M | Buy |
151,200
+71,700
| +90% | +$799K | ﹤0.01% | 4597 |
|
|
2022
Q2 | $854K | Sell |
79,500
-53,600
| -40% | -$441K | ﹤0.01% | 5772 |
|
|
2022
Q1 | $1.26M | Buy |
133,100
+56,500
| +74% | +$530K | ﹤0.01% | 5638 |
|
|
2021
Q4 | $885K | Sell |
76,600
-33,200
| -30% | -$370K | ﹤0.01% | 6147 |
|
|
2021
Q3 | $1.05M | Buy |
109,800
+42,800
| +64% | +$438K | ﹤0.01% | 5816 |
|
|
2021
Q2 | $646K | Sell |
67,000
-54,200
| -45% | -$529K | ﹤0.01% | 6762 |
|
|
2021
Q1 | $1.2M | Buy |
121,200
+106,200
| +708% | +$1.64M | ﹤0.01% | 5112 |
|
|
2020
Q4 | $346K | Buy |
15,000
+1,700
| +13% | +$34.8K | ﹤0.01% | 6215 |
|
|
2020
Q3 | $188K | Buy |
+13,300
| New | +$194K | ﹤0.01% | 6473 |
|
|
2020
Q2 | – | Sell |
-100,700
| Closed | -$930K | – | 7211 |
|
|
2020
Q1 | $930K | Buy |
+100,700
| New | +$957K | ﹤0.01% | 2872 |
|
|
2018
Q4 | – | Sell |
-15,100
| Closed | -$183K | – | 5186 |
|
|
2018
Q3 | $183K | Buy |
+15,100
| New | +$211K | ﹤0.01% | 4723 |
|
|
2018
Q2 | – | Sell |
-22,000
| Closed | -$331K | – | 5154 |
|
|
2018
Q1 | $331K | Buy |
+22,000
| New | +$335K | ﹤0.01% | 3912 |
|
|
2017
Q1 | – | Sell |
-28,900
| Closed | -$144K | – | 4311 |
|
|
2016
Q4 | $144K | Buy |
+28,900
| New | +$200K | ﹤0.01% | 3812 |
|
|
2016
Q1 | – | Sell |
-21,600
| Closed | -$210K | – | 4243 |
|
|
2015
Q4 | $210K | Buy |
+21,600
| New | +$195K | ﹤0.01% | 3532 |
|
|
2015
Q2 | – | Sell |
-20,100
| Closed | -$219K | – | 3762 |
|
|
2015
Q1 | $219K | Buy |
+20,100
| New | +$177K | ﹤0.01% | 2813 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Jane Street's FOLD Position: Q1 2026 in Review
Jane Street reduced its Amicus Therapeutics (FOLD) stake by 59% in Q1 2026, selling an estimated $6.14M and leaving 298,632 shares worth $4.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3719.
Jane Street first reported a position in FOLD in Q3 2013 and has held it in 44 quarters since. The position peaked at $10.3M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Jane Street held 298,632 shares of Amicus Therapeutics worth $4.32M as of Q1 2026.
- Jane Street sold 428,165 Amicus Therapeutics shares in Q1 2026, an estimated $6.14M.
- Amicus Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3719 holding.
- Jane Street first reported a position in Amicus Therapeutics in Q3 2013 and has held it in 44 quarters since.
- Jane Street's Amicus Therapeutics position peaked at $10.3M in Q4 2025.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.